Antonoff Mara B, Mitchell Kyle G, Kim Samuel S, Salfity Hai V, Kotova Svetlana, Ripley Robert Taylor, Neri Alfonso L, Sood Pallavi, Gandhi Saumil G, Elamin Yasir Y, Donington Jessica S, Jones David R, David Elizabeth A, Swisher Stephen G, Opitz Isabelle, Hayanga J W Awori, Rocco Gaetano
Division of Surgery, Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Division of Surgery, Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
Ann Thorac Surg. 2025 Mar;119(3):495-508. doi: 10.1016/j.athoracsur.2024.11.010. Epub 2025 Jan 10.
The use of local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving, with a preponderance of data supporting the benefits of such therapeutic approaches incorporating pulmonary resection for appropriately selected candidates. However, practices vary widely institutionally and regionally, and evidence-based guidelines are lacking.
The Society of Thoracic Surgeons assembled a panel of thoracic surgical oncologists to evaluate and synthesize the available evidence regarding the role of pulmonary resection as LCT. Clinical and research questions of interest were identified, and a complete literature review was conducted. Best practice guidelines were developed accordingly.
The panel identified 7 areas of controversy, and data were assimilated to support the best recommended practices related to these clinical issues. Ultimately, a number of issues in this realm were found to have a high level of evidence to support the role for surgical therapy in patients with stage IV lung cancer. However, the nuances of how these operations are conducted remain in equipoise, without ample evidence to support the extent of resection or nodal dissection.
Clear data exist to support the use of surgical resection of the primary lung tumor as LCT in stage IV lung cancer. Evidence-based recommendations have been provided to guide multidisciplinary teams on the implementation of treatment plans as well as to guide researchers on areas of ongoing need for further investigation.
局部巩固治疗(LCT)在寡转移非小细胞肺癌(NSCLC)患者中的应用正在迅速发展,大量数据支持这种治疗方法对适当选择的患者采用肺切除术的益处。然而,机构和地区之间的实践差异很大,且缺乏循证指南。
胸外科医师协会召集了一组胸外科肿瘤学家,以评估和综合有关肺切除术作为LCT作用的现有证据。确定了感兴趣的临床和研究问题,并进行了全面的文献综述。据此制定了最佳实践指南。
该小组确定了7个争议领域,并汇总了数据以支持与这些临床问题相关的最佳推荐实践。最终,发现该领域的一些问题有大量证据支持手术治疗在IV期肺癌患者中的作用。然而,这些手术如何进行的细微差别仍无定论,没有足够的证据支持切除范围或淋巴结清扫范围。
有明确的数据支持在IV期肺癌中使用手术切除原发性肺肿瘤作为LCT。已提供循证建议,以指导多学科团队实施治疗计划,并指导研究人员确定仍需进一步研究的领域。